Stuart Maudsley | Pharmacology | Best Researcher Award

Posted on by Academic achievements

Prof. Dr. Stuart Maudsley | Pharmacology | Best Researcher Award

Prof. Dr. Stuart Maudsley | Pharmacology – Professor at Moffitt Cancer Center, United States

Dr. Stuart Russell Maudsley is an esteemed researcher and principal investigator whose work has had a profound impact on the field of pharmacology, particularly in the study of G-protein-coupled receptors (GPCRs). His career has been marked by significant contributions to cancer research, aging, and molecular gerontology, leading to the development of innovative therapeutic strategies aimed at treating complex human diseases. Dr. Maudsley’s work focuses on the precision targeting of GPCRs to develop treatments for a wide range of conditions, from cancer to neurodegenerative disorders, with a unique approach that blends basic science with clinical applications. He has been instrumental in leading transformative research at Moffitt Cancer Center and has earned widespread recognition for his contributions in both academia and industry.

Profile:

Scopus

Education:


Dr. Maudsley earned his Ph.D. in Pharmacology from the University of Leeds, UK, after completing a First-Class Bachelor’s degree in Pharmacology at the same institution. His doctoral research focused on electrophysiological and molecular biological studies of Tachykinin receptors, which set the stage for his continued exploration of receptor biology. His academic journey laid the groundwork for a career dedicated to uncovering the complex molecular mechanisms that regulate cellular behavior and how these processes can be manipulated for therapeutic purposes. His early education and research provided a foundation for his later innovations in the field of pharmacology and receptor therapeutics.

Experience:


Dr. Maudsley’s career spans several prestigious roles that highlight his leadership and expertise in pharmacology and receptor biology. He currently serves as the principal investigator at Moffitt Cancer Center, where he directs the Maudsley Lab, focusing on receptor biology and cancer therapeutics. His work is particularly notable for its precision in targeting GPCRs to treat cancer and other complex diseases. Dr. Maudsley also co-founded HeptOME – Receptor Therapeutics, and his position as a Special Science Advisor for the Belgian Superior Health Council reflects his international influence. His experience in both academic and industry settings has allowed him to bridge the gap between cutting-edge research and real-world therapeutic solutions.

Research Interests:


Dr. Maudsley’s primary research interest lies in the molecular and pharmacological study of GPCRs, a class of receptors that play a crucial role in various cellular processes. He focuses on understanding how these receptors regulate human diseases, particularly cancer, aging, and neurodegenerative disorders. By investigating the intricate mechanisms of GPCR signaling, Dr. Maudsley aims to develop novel targeted therapies that can improve treatment outcomes in these complex diseases. His research extends to systems pharmacology, which integrates multidimensional approaches to identify new drug targets and improve therapeutic strategies. Dr. Maudsley is particularly interested in the therapeutic application of GPCR-targeted medicines and their potential to treat diseases with unmet medical needs.

Awards:


Dr. Maudsley has received numerous accolades for his pioneering research in pharmacology and receptor biology. His work has been consistently recognized for its potential to revolutionize therapeutic strategies for cancer and aging-related diseases. He has been invited to speak at prestigious international conferences and has received several awards from scientific and medical societies for his contributions to understanding receptor biology. His recognition as a co-founder of HeptOME – Receptor Therapeutics further highlights his entrepreneurial spirit and ability to translate scientific discoveries into practical applications that benefit patients worldwide.

Publications:


Dr. Maudsley has an extensive publication record, contributing to major scientific journals and collaborative research projects. A few notable publications include:

  1. Maudsley S., Leysen H., van Gastel J., Martin B. (2021). Systems Pharmacology: Enabling Multidimensional Therapeutics, Reference Module in Biomedical Sciences. 📖
  2. Maudsley S., Schrauwen C., Harputluoğlu İ., Walter D., Leysen H., McDonald P. (2023). GPR19 Coordinates Multiple Molecular Aspects of Stress Responses Associated with the Aging Process, Int J Mol Sci. 🔬
  3. Schreurs G., Maudsley S., Nast C., Praet M., Da Silva Fernandes S., Boor P., D’Haese P., De Broe M.E., Vervaet B.A. (2023). Chronic Dehydration Induces Injury Pathways in Rats, Sci Rep. 🧪
  4. Maudsley S., Leysen H., Walter D., Vandoren R. (2023). GPCRs Regulate DNA Integrity, Encyclopedia – Biochemistry and Molecular Biology. 📑
  5. Coppens V., De Wachter O., Goossens J., Hendrix J., Maudsley S., Azmi A., van Gastel J., Van Saet A., Lauwers T., Morrens M. (2020). Profiling of Peripheral Blood Mononuclear Cells for Schizophrenia Biomarkers, Neuropsychobiology. 🧠
  6. Van Meenen J., Leysen H., Chen H., Baccarne R., Walter D., Martin B., Maudsley S. (2022). Making Biomedical Sciences Publications More Accessible for Machines, Med Health Care Philos. 💻
  7. Leysen H., Maudsley S., Van Gastel J., Martin B. (2021). The RXFP3 Receptor is a Modulator of Aging-Related Disease, Int J Mol Sci. 🧬

Conclusion:


Dr. Stuart Russell Maudsley’s extensive contributions to pharmacology, especially in the area of GPCRs and their role in complex diseases, make him an exceptional candidate for the Best Researcher Award. His research, which bridges the gap between basic science and clinical applications, continues to shape the future of precision medicine. Through his innovative work at Moffitt Cancer Center and his involvement in entrepreneurial ventures like HeptOME – Receptor Therapeutics, Dr. Maudsley has made a lasting impact on both academia and industry. His leadership in the field and his commitment to advancing therapeutic solutions for cancer, aging, and neurodegenerative diseases position him as a truly deserving nominee for this prestigious award.

Rohitash Yadav | Drug Discovery | Young Scientist Award

Posted on by Academic achievements

Dr. Rohitash Yadav | Drug Discovery | Young Scientist Award 

Assistant Professor at Pacific Medical College and Hospital, Udaipur, India

Dr. Rohitash Yadav is a highly accomplished researcher with expertise in pharmacology, computational biology, and drug design. Currently serving as an Assistant Professor at Pacific Medical College and Hospital, Udaipur, Dr. Yadav’s research focuses on finding innovative solutions for cancer treatment and infectious diseases. His extensive work on SARS-CoV-2 and multiple myeloma has earned him widespread recognition. Dr. Yadav has authored numerous high-impact scientific articles and has consistently been honored for his contributions to biomedical research.

Profile:

ORCID

Education:

Dr. Yadav holds a PhD from the All India Institute of Medical Sciences (AIIMS), Rishikesh, where he specialized in pharmacology and computational drug design. Prior to this, he earned a Master’s degree in Medical Pharmacology from the Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh. His academic journey has equipped him with the necessary skills to lead cutting-edge research projects in both academia and healthcare.

Experience:

Dr. Yadav’s professional journey includes significant research and academic roles. He is currently an Assistant Professor at Pacific Medical College and Hospital, Udaipur. Before that, he served as a Junior Research Fellow at AIIMS Rishikesh, where he was instrumental in leading research initiatives aimed at drug discovery and the development of therapeutic strategies for multiple myeloma and viral diseases. His broad research collaborations span across global institutions, reflecting his leadership in the biomedical field.

Research Interests:

Dr. Yadav’s primary research areas include computational drug design, molecular docking, and in-silico and in-vitro pharmacological studies. He is deeply engaged in the study of potential inhibitors targeting various cancerous pathways, with a strong emphasis on multiple myeloma and COVID-19 therapies. His interdisciplinary approach, combining computational biology with clinical pharmacology, allows for the identification of novel therapeutic compounds and proteins that can be targeted to treat life-threatening diseases.

Awards:

Dr. Yadav has been the recipient of numerous prestigious awards throughout his academic career. His contributions to the biomedical field were recognized by the Best Researcher Award at AIIMS Rishikesh in 2022 and 2023. Additionally, he was awarded the Junior Research Fellowship from AIIMS Rishikesh between 2020-2022. His work on computational biology and drug design has earned him accolades from national and international conferences.

Publications:

Dr. Yadav has an impressive array of publications, including some of the most-cited works in the field. Key publications include:

Yadav R, Mathur I, et al. Dostarlimab: Review on success story and clinical trials. Critical Reviews in Oncology/Hematology (2024). doi:10.1016/j.critrevonc.2024.104374 – Cited by 12 articles.

Gupta SM, Jain NK, Yadav R, et al. Computational investigation of the interaction of novel indene methylene analogues with acetylcholinesterase. Letters in Drug Design & Discovery (2023). doi:10.2174/1570180819666220623144252 – Cited by 18 articles.

Yadav R, Nath UK, et al. Identification and in-vitro analysis of potential proteasome inhibitors for multiple myeloma. Biomedicine & Pharmacotherapy (2023). doi:10.1016/j.biopha.2022.113963 – Cited by 25 articles.

Yadav R, Hasan S, et al. Molecular docking, DFT analysis, and dynamics simulation of natural bioactive compounds targeting ACE2 and TMPRSS2 dual binding sites of spike protein of SARS CoV-2. Journal of Molecular Liquids (2021). doi:10.1016/j.molliq.2021.116942 – Cited by 34 articles.

Yadav R, Celik I, et al. Interactions of the receptor-binding domain of SARS-CoV-2 variants with hACE2: Insights from molecular docking analysis. Biology (2021). doi:10.3390/biology10090880 – Cited by 40 articles.

Yadav R, Kumar JK, et al. Host cell and SARS-CoV-2-associated molecular structures as potential therapeutic targets. Cells (2021). doi:10.3390/cells10092427 – Cited by 28 articles.

Yadav R, Celik I, et al. Investigation of reactive properties, adsorption on fullerene, DFT, molecular dynamics simulation of an anthracene derivative targeting dihydrofolate reductase and human dUTPase. Journal of Biomolecular Structure and Dynamics (2021). doi:10.1080/07391102.2021.1953602 -Cited by 20 articles.

Yadav R, Kumar JK, et al. Insights into COVID-19 vaccine development based on immunogenic structural proteins of SARS-CoV-2. Cells (2021). doi:10.3390/cells10112949 – Cited by 35 articles.

Conclusion:

Dr. Rohitash Yadav’s proven track record in high-impact research, coupled with his leadership in the scientific community and consistent recognition through awards, strongly support his candidacy for the Young Scientist Award. His innovative work in pharmacology, especially in computational drug design, and his proactive engagement with biomedical research make him a well-rounded candidate poised to make significant contributions in the future. However, further emphasis on interdisciplinary collaborations and public outreach could elevate his profile even higher.